H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Argenx to $482 from $480 and keeps a Buy rating on the shares. The analyst now includes into the stock’s valuation some of the indications the company has most recently announced it is pursuing with efgartigimod, specifically thyroid eye disease, Sjogren’s syndrome and ANCA-associated vasculitis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- TipRanks ‘Perfect 10’ List: 2 Top Stocks That Analysts Are Placing Their Bets On
- argenx Announces Annual General Meeting of Shareholders on May 2, 2023
- argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
- Argenx announces MHRA approval of VYVGART
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations